Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Will Continue To Invest To Drive Growth

CEO Peter Goldschmidt Is Seeking Both Organic And Inorganic Expansion

Executive Summary

After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.

You may also be interested in...



Nidda Investment Group Takes Full Ownership Of Stada Through Settlements With Shareholders

Nidda Healthcare, investment vehicle controlled by Bain Capital and Cinven, secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of 10 euro cents per outstanding share for the remaining shareholders.

Stada Settlements Secure Squeeze-Out

Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of €0.10 per outstanding share for the remaining shareholders.

Stada Names New Global Development Head

Stada has named Yann Brun to become the group’s new head of global development, portfolio, regulatory and business development, replacing Robert Knerr. The move is the latest in a string of key appointments at Stada as the firm builds on a series of acquisitions and deals.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel